araag2/HINT huggingface dataset:
Clinical trial NCT01434160 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: skyla (levonorgestrel, bay86-5028)
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  The subject has signed and dated the informed consent form (ICF)

          -  The subject is female, generally healthy, post-menarcheal, nulliparous or parous,
             requiring contraception, and is under 18 years of age at the Screening visit

          -  The subject has regular menstrual cycles without hormonal contraceptive use (at
             regular intervals of 21-35 days)

          -  In the opinion of the investigator, the subject has general and uterine conditions
             suitable for the insertion of levonorgestrel intrauterine contraceptive system (LCS12)
             (uterine sound depth 6-10 cm)

          -  Has clinically normal safety laboratory results

          -  The subject has a normal or clinically insignificant cervical smear (i.e. one that
             does not require further follow up according to Bethesda or a comparable system)

          -  The subject is willing and able to attend the scheduled study visits and to comply
             with the study procedures

        Exclusion Criteria:

          -  Known or suspected pregnancy or is lactating

          -  Vaginal delivery, cesarean delivery, or abortion less than 6 weeks before Visit 1

          -  History of ectopic pregnancies

          -  Infected abortion or postpartum endometritis less than 3 months before Visit 1

          -  Abnormal uterine bleeding of unknown origin

          -  Any lower genital tract infection (until successfully treated)

          -  Acute or history of recurrent pelvic inflammatory disease

          -  Congenital or acquired uterine anomaly
Clinical trial NCT00525044 (phase 3, status: completed)
Conditions: pharyngitis
ICD codes: A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8
Drugs: ambroxol, placebo
SMILES: NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        1. Patients having a sore throat with acute viral pharyngitis. 2. Female and male ambulant
        patients between the ages of 18 and 65. 3. The throat pain intensity is rated at least
        severe on the VRS (PI). 4. Written Informed Consent is given by the patient. 5. Compliance
        by the patient seems guaranteed.

          1. Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary
             infection (clinical findings; inter alia assessment of exudate).

          2. First indication of symptoms of acute pharyngitis (e.g., sore throat) occurred more
             than 3 days ago already.

          3. Counting of white blood cell in blood routine examination exceeds 10?109/L.

          4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.

          5. Broncho-motor disorders or concomitant diseases with relatively large quantities of
             secretion (danger of secretion blockage).

          6. Known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet.

          7. Previous and/or existing tumour condition.

          8. Pregnancy and/or breast-feeding.

          9. Alcohol, and/or drug abuse.

         10. Simultaneous participation in another clinical trial.
Clinical trial NCT00736099 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
SMILES: CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Signed and dated written informed consent in accordance with the GCP and local
             legislation.

          2. Patients completing the entire treatment period as a double blind trial whether or not
             they have been treated with rescue medication.

        Exclusion criteria:

          1. Patients who meet one or more of the withdrawal criteria of the treatment period of
             the previous trial.

          2. Pre-menopausal women (last menstruation =< 1 year prior to signing informed consent)
             who:

               -  are nursing or pregnant,

               -  or are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include transdermal patch, intra
                  uterine devices/systems (IUDs/IUSs), oral, implantable or injectable
                  contraceptives, true sexual abstinence (when this is in line with the preferred
                  and usual lifestyle of the patient; periodic abstinence [e.g. calendar,
                  ovulation, symptothermal, post-ovulation methods] and withdrawal are not
                  acceptable methods of birth control) and vasectomised partners. No exception will
                  be made.

          3. Alcohol abuse within the 3 months prior to informed consent that would interfere with
             trial participation.

          4. Drug abuse which, in the opinion of the investigator, would interfere with trial
             participation.

          5. Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of the trial medication.
Clinical trial NCT00457691 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo
SMILES: FC1=CNC(=O)NC1=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, FC1=CNC(=O)NC1=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed (histologically or cytologically) colorectal adenocarcinoma with metastatic
             disease.

          -  Not received previous therapy for metastatic colorectal disease but for whom FOLFIRI
             treatment is clinically indicated.

          -  Adequate organ function defined by blood test.

        Exclusion Criteria:

          -  History of another primary cancer in the last 3 years.

          -  Previous full field radiotherapy within the last 4 weeks or limited field radiotherapy
             within 2 weeks of enrolling into the study. Or previous radiation treatment of more
             that 30% of the bone marrow.

          -  History of presence of brain metastasis, spinal cord compression carcinomatous
             meningitis or leptomeningeal disease.
Clinical trial NCT00637377 (phase 3, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent.

          -  Men and women >/=50 years of age.

          -  Active primary or recurrent subfoveal CNV lesions secondary to AMD, including
             juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA)
             in the study eye.

          -  ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to
             20/320) in the study eye at 4 meters.

          -  Willing, committed, and able to return for ALL clinic visits and complete all
             study-related procedures.

          -  Able to read, (or, if unable to read due to visual impairment, be read to verbatim by
             the person administering the informed consent or a family member) understand and
             willing to sign the informed consent form.

        Exclusion Criteria:

          -  Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular
             AMD, except dietary supplements or vitamins.

          -  Any prior or concomitant therapy with another investigational agent to treat
             neovascular AMD in the study eye.

          -  Any prior treatment with anti-VEGF agents in the study eye.

          -  Total lesion size >12 disc areas (30.5 mm, including blood, scars and
             neovascularization) as assessed by FA in the study eye.

          -  Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the
             blood is under the fovea and is 1 or more disc areas in size in the study eye (if the
             blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible
             CNV).

          -  Scar or fibrosis making up >50% of the total lesion in the study eye.

          -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.

          -  Presence of retinal pigment epithelial tears or rips involving the macula in the study
             eye.

          -  History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.

          -  Presence of other causes of CNV in the study eye.

          -  Prior vitrectomy in the study eye.

          -  History of retinal detachment or treatment or surgery for retinal detachment in the
             study eye.

          -  Any history of macular hole of stage 2 and above in the study eye.

          -  Any intraocular or periocular surgery within 3 months of Day 1 on the study eye,
             except lid surgery, which may not have taken place within 1 month of Day 1, as long as
             it is unlikely to interfere with the injection.

          -  History or clinical evidence of diabetic retinopathy, diabetic macular edema or any
             retinal vascular disease other than AMD in either eye.
Clinical trial NCT00454389 (phase 3, status: unknown status)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have predominantly classic, minimally classic, or occult with no classic
             lesions, as determined by the Investigator, secondary to AMD, with a total lesion size
             (including blood, scarring, and neovascularization) of < 12 total disc areas (21.24
             mm2), and a GLD ≤5.4 mm

          -  Subjects must be age 50 or older

        Exclusion Criteria:

          -  Subjects with prior or concurrent subfoveal CNV therapy including thermal laser
             photocoagulation (with or without photographic evidence), photodynamic therapy,
             injections with Macugen®, intravitreal or subretinal steroids, transpupillary
             thermotherapy (TTT), and systemic anti-angiogenic or intravitreal anti-angiogenic
             agents in study eye. (Note: This includes subjects with no known history, but with
             photographic evidence of prior therapy)

          -  Subjects who underwent previous radiation therapy to the eye, head or neck

          -  Subjects that have been previously diagnosed or have retinal findings consistent with
             Type 1 or Type 2 Diabetes Mellitus
Clinical trial NCT01254604 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: preservative-free tafluprost or vehicle, preservative-free timolol maleate
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma,
             capsular glaucoma/pseudoexfoliation, or ocular hypertension

          -  Has been using ocular hypotensive medication on a stable treatment regimen for at
             least 30 days prior to screening, or is treatment-naive (has never used or has not
             used ocular hypotensive medication for the last 4 weeks prior to screening)

          -  Able to discontinue all topical and/or systemic ocular hypotensive medication during
             the washout period (up to 4 weeks pre-study)

          -  Best-corrected early treatment of diabetic retinopathy study (ETDRS) visual acuity of
             20/80 or better in each eye

          -  Willing and able to avoid wearing contact lenses from 4 weeks prior to dosing with
             study medication through 24 hours after final dosing

          -  Willing and able to self-administer or has an able person available on a daily basis
             to assist with administration of study medications

          -  Participant with reproductive potential must agree to remain abstinent (unless
             abstinence is not a locally acceptable method of contraception) or use highly
             effective methods of birth control (hormonal contraceptives, intrauterine device,
             diaphragm, condoms and vasectomy) within the projected duration of the study

          -  Able to refrigerate study drug at home.

        Exclusion Criteria:

          -  Mean IOP >36 mmHg in either eye at screening

          -  Unable to use study medication in the affected eye(s)

          -  History of any inflammatory ocular surface disease or a history of anterior or
             posterior uveitis in either eye within 6 months prior to screening

          -  History of retinal detachment, proliferative diabetic retinopathy, or any progressive
             retinal disease

          -  Significant visual field loss or evidence of progressive visual loss within the last
             year

          -  Intraocular surgery in either eye in the last 4 months

          -  Any glaucoma surgery, refractive surgery, or penetrating keratoplasty in either eye

          -  Currently on two or more anti-glaucoma medications (except Cosopt™ or its generic
             formulation)

          -  Previously used tafluprost

          -  History of cardiovascular disorder within 6 months of screening

          -  History of bronchial asthma, wheezing, chronic obstructive pulmonary disease (COPD) or
             other pulmonary disease, abnormal chest x-ray, or has current active pneumonia.
Clinical trial NCT01516840 (phase 3, status: completed)
Conditions: deep vein thrombosis
ICD codes: I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593
Drugs: rivaroxaban (xarelto, bay59-7939), rivaroxaban (xarelto, bay59-7939), unfractionated heparin, warfarin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women >/= 20 years of age in patients with confirmed acute symptomatic
             proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE)

        Exclusion Criteria:

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current episode of DVT

          -  More than 48 hours pre-randomization treatment with therapeutic dosages of
             anti-coagulant treatment or more than a single dose of warfarin from the onset of the
             current episode of DVT to randomization

          -  Calculated creatinine clearance (CLCR) < 30 mL/min

          -  Subjects with hepatic disease which is associated with coagulopathy leading to a
             clinically relevant bleeding risk

          -  Active bleeding or high risk for bleeding contraindicating treatment with unfractioned
             Heparin (UFH) or warfarin

          -  Systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg
Clinical trial NCT01513460 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237 50µg once daily, tiotropium 18µg once daily, flu/sal, nva237 placebo + tiotropium placebo.
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Moderate to Severe COPD (Stage II or Stage III) according to the GOLD
             2010 guideline

          -  Current or ex-smokers who have a smoking history of at least 10 pack years

          -  Qualifying FEV1 at Visit 2 (day -7)

        Exclusion Criteria:

          -  Patients with a history of asthma or a history of high blood eosinophil count
             (>600/mm³)

          -  Patients with concomitant pulmonary disease

          -  Patients with lung lobectomy or lung volume reduction or lung transplantation

          -  Patients with α-1 antitrypsin deficiency

          -  Patients who have had live attenuated vaccinations within 30 days prior to screening
             visit or during run-in period

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00466193 (phase 3, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: zolpidem tartrate sublingual tablet, placebo
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with history of sleeplessness

        Exclusion Criteria:

          -  Allergic to investigational drug

          -  Any conditions and medications that may interfere with study drug evaluation
Clinical trial NCT00089895 (phase 3, status: completed)
Conditions: myocardial ischemia, acute coronary syndrome
ICD codes: I25.6, P29.4, I24.0
Drugs: eptifibatide (integrilin), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give informed consent and comply with study procedures and
             follow-up through 1 year.

          -  Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours.

          -  Able to be randomized into the trial within 12 hours of having symptoms of acute
             coronary syndrome.

          -  Experiencing symptoms of cardiac ischemia at rest (angina or anginal equivalent) with
             episode(s) lasting at least 10 minutes and have at least 2 of the following:

               -  60 years of age or more

               -  Electrocardiogram changes (ECG)

               -  Elevated troponin (protein released in the blood stream in people suffering from
                  acute coronary syndrome) or CK-MB levels

          -  Or have all 3 of the following:

               -  Prior history of cardiovascular disease

               -  Elevated troponin or CK-MB levels

               -  50-59 years of age

        Exclusion Criteria:

          -  pregnancy (known or suspected)

          -  renal dialysis within 30 days prior to randomizing in study

          -  other serious illnesses or any condition that the investigator feels would pose a
             significant hazard to the patient if the investigational therapy was to be initiated

          -  Stroke (hemorrhagic stroke at any time or non-hemorrhagic stroke within previous 7
             days), central nervous system damage (such as neoplasm, aneurysm, intracranial
             surgery), bleeding disorders (including gastrointestinal bleeding), or recent major
             surgery or major trauma.

          -  History of certain hematologic problems following treatment with heparin or
             eptifibatide.

          -  Therapy with certain related drugs within a short time before randomization into the
             trial.
Clinical trial NCT00170196 (phase 3, status: completed)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: prednisone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

        Clinical symptoms of community-acquired pneumonia:

          -  Fever, cough, sputum, pleural pain, dyspnoea

          -  Radiological symptoms of pneumoniä

        Exclusion Criteria:

          -  Any conditions wich requires corticosteroid therapy.

          -  Pregnancy of lactation

          -  Malignancy

          -  Immune-compromised patients (eg chemotherapy or AIDS)

          -  Pre-treatment with macrolide for >24 hours
Clinical trial NCT01198327 (phase 3, status: completed)
Conditions: retinal vein occlusion
ICD codes: H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent and authorization of use and disclosure of protected health
             information

          -  Age greater than or equal to 18 years

          -  Completion of 12 months in BRAVO or CRUISE trials, with subsequent follow-up in the
             HORIZON extension study. Exit from HORIZON should be within 90 days of enrollment

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception. The following are considered
             effective means of contraception: surgical sterilization or use of oral
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

          -  Any condition that the investigator believes would pose a significant hazard to the
             subject if investigational therapy were initiated.

          -  Inability to comply with study or follow up procedures

          -  Participation in another simultaneous medical investigation or trial